BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 35144648)

  • 21. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
    Schmidts A; Ormhøj M; Choi BD; Taylor AO; Bouffard AA; Scarfò I; Larson RC; Frigault MJ; Gallagher K; Castano AP; Riley LS; Cabral ML; Boroughs AC; Velasco Cárdenas RM; Schamel W; Zhou J; Mackay S; Tai YT; Anderson KC; Maus MV
    Blood Adv; 2019 Nov; 3(21):3248-3260. PubMed ID: 31698455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
    D'Agostino M; Raje N
    Leukemia; 2020 Jan; 34(1):21-34. PubMed ID: 31780814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
    Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN
    Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.
    Timmers M; Roex G; Wang Y; Campillo-Davo D; Van Tendeloo VFI; Chu Y; Berneman ZN; Luo F; Van Acker HH; Anguille S
    Front Immunol; 2019; 10():1613. PubMed ID: 31379824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells.
    Wang Q; He F; He W; Huang Y; Zeng J; Zi F; Zheng J; Fei Y; Xu J; Song Y; Ye X; Lai R; Ye L; Zhu B
    Cell Immunol; 2021 May; 363():104342. PubMed ID: 33765541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8
    Bae J; Samur M; Richardson P; Munshi NC; Anderson KC
    Leukemia; 2019 Sep; 33(9):2208-2226. PubMed ID: 30872779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
    Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR
    Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 30. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
    Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
    Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
    Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
    Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma.
    Salem DA; Maric I; Yuan CM; Liewehr DJ; Venzon DJ; Kochenderfer J; Stetler-Stevenson M
    Leuk Res; 2018 Aug; 71():106-111. PubMed ID: 30053652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel BCMA Immunohistochemistry Assay Reveals a Heterogenous and Dynamic BCMA Expression Profile in Multiple Myeloma.
    Zhang M; Gray F; Cushman I; Wurmser A; Chan H; Couto S; Wang M; Nakayama Y; Hagner P; Al-Masri H; Williams S; Hersey S
    Mod Pathol; 2023 Apr; 36(4):100050. PubMed ID: 36788077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells].
    Zhong MJ; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):804-811. PubMed ID: 31775477
    [No Abstract]   [Full Text] [Related]  

  • 37. Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma.
    Dalla Palma B; Marchica V; Catarozzo MT; Giuliani N; Accardi F
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32961764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCMA-targeting approaches for treatment of multiple myeloma.
    Chen Y; Nagarajan C; Tan MS; Martinelli G; Cerchione C
    Panminerva Med; 2021 Mar; 63(1):28-36. PubMed ID: 32955181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.
    Smith EL; Staehr M; Masakayan R; Tatake IJ; Purdon TJ; Wang X; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Riviere I; Liu C; Brentjens RJ
    Mol Ther; 2018 Jun; 26(6):1447-1456. PubMed ID: 29678657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies.
    Alexaki VI; Pelekanou V; Notas G; Venihaki M; Kampa M; Dessirier V; Sabour-Alaoui S; Stathopoulos EN; Tsapis A; Castanas E
    Endocrinology; 2012 Feb; 153(2):739-49. PubMed ID: 22166983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.